Rosetta Genomics, UC Davis Partner on Patient Response to Bladder Cancer Treatment
June 28, 2011
Rosetta Genomics, UC Davis Partner on Patient Response to Bladder Cancer Treatment
The company and university are developing and validating a microRNA profile for muscle-invasive bladder cancer that may be used to predict response to neoadjuvant chemotherapies.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- New York Gives Final Approval for Rosetta Genomics' miRview Lung Assay
November 6, 2012 / GenomeWeb Daily News - Medicare Contractor Confirms Coverage for One Rosetta Genomics Test, Denies Coverage for Two Others
June 13, 2013 / GenomeWeb Daily News - Rosetta Genomics Looking Beyond Cancer to Cardio, Neuro, Women's Health for Blood-Based MDx Program
June 11, 2013 / BioArray News - Rosetta Inks Agreement with Three Rivers to Offer Access to Cancer Test
June 7, 2013 / GenomeWeb Daily News - Rosetta Genomics, Prime Health Reach Deal for Coverage of MiRview Mets2 Assay
May 20, 2013 / GenomeWeb Daily News